363 related articles for article (PubMed ID: 11684056)
21. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
[TBL] [Abstract][Full Text] [Related]
22. Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice.
Oshikawa T; Kuroiwa H; Yano R; Yokoyama H; Kadoguchi N; Kato H; Araki T
Cell Mol Neurobiol; 2009 Jul; 29(5):769-77. PubMed ID: 19370411
[TBL] [Abstract][Full Text] [Related]
23. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
24. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Schlüter OM; Fornai F; Alessandrí MG; Takamori S; Geppert M; Jahn R; Südhof TC
Neuroscience; 2003; 118(4):985-1002. PubMed ID: 12732244
[TBL] [Abstract][Full Text] [Related]
25. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity.
Oeckl P; Ferger B
Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.
Anderson DW; Neavin T; Smith JA; Schneider JS
Brain Res; 2001 Jun; 905(1-2):44-53. PubMed ID: 11423078
[TBL] [Abstract][Full Text] [Related]
28. Methamphetamine and dopamine neurotoxicity: differential effects of agents interfering with glutamatergic transmission.
Boireau A; Bordier F; Dubédat P; Doble A
Neurosci Lett; 1995 Jul; 195(1):9-12. PubMed ID: 7478259
[TBL] [Abstract][Full Text] [Related]
29. An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Archer T; Fredriksson A
J Neural Transm (Vienna); 2003 Feb; 110(2):183-200. PubMed ID: 12589577
[TBL] [Abstract][Full Text] [Related]
30. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice.
Parain K; Marchand V; Dumery B; Hirsch E
Brain Res; 2001 Feb; 890(2):347-50. PubMed ID: 11164803
[TBL] [Abstract][Full Text] [Related]
31. Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice.
Vaglini F; Pardini C; Bonuccelli U; Maggio R; Corsini GU
Brain Res; 2003 May; 973(2):298-302. PubMed ID: 12738074
[TBL] [Abstract][Full Text] [Related]
32. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
33. (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice.
Vaglini F; Fascetti F; Fornai F; Maggio R; Corsini GU
Brain Res; 1994 Dec; 668(1-2):194-203. PubMed ID: 7704605
[TBL] [Abstract][Full Text] [Related]
34. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
35. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
36. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
37. The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra.
Wedzony K; Czyrak A; Maćkowiak M; Fijał K
Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):517-27. PubMed ID: 8740145
[TBL] [Abstract][Full Text] [Related]
38. Screening of novel pentacyclo-undecylamines for neuroprotective activity.
Geldenhuys WJ; Terre'Blanche G; Van der Schyf CJ; Malan SF
Eur J Pharmacol; 2003 Jan; 458(1-2):73-9. PubMed ID: 12498909
[TBL] [Abstract][Full Text] [Related]
39. Effect of D-Ala
Verma MK; Goel R; Nandakumar K; Nemmani KVS
Eur J Pharmacol; 2017 Jun; 804():38-45. PubMed ID: 28366809
[TBL] [Abstract][Full Text] [Related]
40. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
